Drugs / allogeneic NK cells
allogeneic NK cells
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07225439 | Sep 2026 → Dec 2027 expected | chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, high grade B-cell lymphoma, mantle cell lymphoma +2 | Paolo Caimi, MD | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT00877110 | Apr 2009 → Jan 2019 | bone marrow disorder, neuroblastoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04162158 | Mar 2019 → Oct 2022 | hepatocellular carcinoma | Beijing 302 Hospital | Unknown | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2020-04-21 | Kite, A Gilead Company | Gilead, Kite and oNKo-innate Announce Research Collaboration to Discover Cancer Immunotherapies Focused on Natural Killer (NK) Cells kitepharma.com ↗ |
| 2020-04-21 | Gilead Sciences | Gilead, Kite and oNKo-innate Announce Research Collaboration to Discover Cancer Immunotherapies Focused on Natural Killer (NK) Cells gilead.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | allogeneic NK cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00877110 ↗ |
| Known as | natural killer (NK) cells | “natural killer (NK) cells” NCT00877110 ↗ |
| Known as | NK cells | “natural killer (NK) cells” NCT00877110 ↗ |
| Modality | Cell therapy | “combination of adoptive NK cell therapy with RT significantly improved therapeutic efficacy” PMID 37981041 ↗ Nov 2023 |
| Route | Intravenous | “Allogeneic NK cells are given intravenously (IV) weekly for 3 weeks on Days 0, 7, 14.” NCT07225439 ↗ |